Open AccessA Single-centre, Before-After Study of the Short- and Long-term Efficacy of Narivent® in the Treatment of Nasal Congestion
Author(s) -
Valerio Damiani,
Angelo Camaioni,
Claudio Viti,
AS Scirè,
Giada Morpurgo,
Darío Gregori
Publication year - 2012
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/030006051204000534
Subject(s) - nasal congestion , medicine , nostril , wilcoxon signed rank test , nose , otorhinolaryngology , nasal polyps , visual analogue scale , adverse effect , sinusitis , nonallergic rhinitis , anesthesia , surgery , asthma , mann–whitney u test
Objective: Nasal congestion is a common symptom in allergic and nonallergic rhinitis, rhinosinusitis and nasal polyposis. The present study evaluated the clinical effectiveness of Narivent®, an osmotically-acting medical device with anti -oedematous and anti-inflammatory effects, in nasal congestion.Methods: A single-centre, prospective study with a pre- post design and consecutive patient enrolment was conducted in an Italian otolaryngology department. Patients with persistent nasal congestion were allocated to treatment groups as follows: group 1 ( n = 36) treated for 7 days; group 2 ( n = 56) treated for 30 days. In each group, patients received two puffs of Narivent® into each nostril twice daily. Symptom severity was assessed subjectively on a 0 - 10 visual analogue scale, and objectively by the presence/absence of signs and symptoms. Differences in subjective and objective severity measures before and after treatment were compared using Wilcoxon's signed rank test.Results: All symptoms and objective scores improved after treatment with Narivent® for 7 or 30 days and no adverse effects were reported by the patients in either group.Conclusion: Narivent® appears to be efficacious in treating nasal congestion over a 7- or a 30-day period.